These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33188385)

  • 1. Population pharmacokinetics and dosing optimization of azlocillin in neonates with early-onset sepsis: a real-world study.
    Wu YE; Wang T; Yang HL; Tang BH; Kong L; Li X; Gao Q; Li X; Yao BF; Shi HY; Huang X; Wang WQ; Jacqz-Aigrain E; Allegaert K; van den Anker J; Tian XY; Zhao W
    J Antimicrob Chemother; 2021 Feb; 76(3):699-709. PubMed ID: 33188385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utiliy of a model-based piperacillin dose in neonates with early-onset sepsis.
    Wu YE; Hou SS; Fang ZY; Tang BH; Yao BF; Dong YN; Li X; Shi HY; Zheng Y; Hao GX; Huang X; Van Den Anker J; Yu YH; Zhao W
    Br J Clin Pharmacol; 2022 Mar; 88(3):1179-1188. PubMed ID: 34450681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose of cefotaxime in neonates with early-onset sepsis: A developmental pharmacokinetic model-based evaluation.
    Shang ZH; Wu YE; Lv DM; Zhang W; Liu WQ; van den Anker J; Xu Y; Zhao W
    Front Pharmacol; 2022; 13():916253. PubMed ID: 36160425
    [No Abstract]   [Full Text] [Related]  

  • 4. Population Pharmacokinetics and Dosing Optimization of Amoxicillin in Neonates and Young Infants.
    Tang BH; Wu YE; Kou C; Qi YJ; Qi H; Xu HY; Leroux S; Huang X; Zhou Y; Zheng Y; Jacqz-Aigrain E; Shen AD; Zhao W
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of a model-based amoxicillin dosage regimen in neonates with early-onset sepsis.
    Kou C; Li DF; Tang BH; Dong L; Yao BF; van den Anker J; You DP; Wu YE; Zhao W
    Br J Clin Pharmacol; 2022 Nov; 88(11):4950-4955. PubMed ID: 36057912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics and dosing optimization of mezlocillin in neonates and young infants.
    Zhou J; Jiang L; Zhang ZL; Wang ZR; Zhang YX; Lin X; Tang BH; Yao BF; Guo ZX; Yang JJ; Van Den Anker J; Wu YE; Zhao W
    J Antimicrob Chemother; 2022 Jul; 77(8):2238-2244. PubMed ID: 35662337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics-pharmacodynamics of ceftazidime in neonates and young infants: Dosing optimization for neonatal sepsis.
    Li X; Qi H; Jin F; Yao BF; Wu YE; Qi YJ; Kou C; Wu XR; Luo XJ; Shen YH; Zheng X; Wang YH; Xu F; Jiao WW; Li JQ; Xiao J; Dong YN; Du B; Shi HY; Xu BP; Shen AD; Zhao W
    Eur J Pharm Sci; 2021 Aug; 163():105868. PubMed ID: 33951483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
    Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and dosing optimization of latamoxef in neonates and young infants.
    Qi H; Kou C; Qi YJ; Tang BH; Wu YE; Jin F; Luo XJ; Shen YH; Guo YJ; Qi X; Wang YC; Dong Q; Chen XK; Shi HY; Zheng Y; Zhao W; Shen AD
    Int J Antimicrob Agents; 2019 Mar; 53(3):347-351. PubMed ID: 30472290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.
    Zhao W; Hill H; Le Guellec C; Neal T; Mahoney S; Paulus S; Castellan C; Kassai B; van den Anker JN; Kearns GL; Turner MA; Jacqz-Aigrain E;
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6572-80. PubMed ID: 25155587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial.
    Hill LF; Turner MA; Lutsar I; Heath PT; Hardy P; Linsell L; Jacqz-Aigrain E; Roilides E; Sharland M;
    Trials; 2020 Apr; 21(1):329. PubMed ID: 32293527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Population and Developmental Pharmacokinetic Analysis To Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.
    Leroux S; Roué JM; Gouyon JB; Biran V; Zheng H; Zhao W; Jacqz-Aigrain E
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6626-6634. PubMed ID: 27572399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Penicillin G in Preterm and Term Neonates.
    Padari H; Metsvaht T; Germovsek E; Barker CI; Kipper K; Herodes K; Standing JF; Oselin K; Tasa T; Soeorg H; Lutsar I
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.
    Thorsted A; Kristoffersson AN; Maarbjerg SF; Schrøder H; Wang M; Brock B; Nielsen EI; Friberg LE
    J Antimicrob Chemother; 2019 Oct; 74(10):2984-2993. PubMed ID: 31273375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
    Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
    Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimisation of vancomycin exposure in neonates based on the best level of evidence.
    Dao K; Guidi M; André P; Giannoni E; Basterrechea S; Zhao W; Fuchs A; Pfister M; Buclin T; Csajka C
    Pharmacol Res; 2020 Apr; 154():104278. PubMed ID: 31108184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis.
    Roberts JA; Kirkpatrick CM; Roberts MS; Dalley AJ; Lipman J
    Int J Antimicrob Agents; 2010 Feb; 35(2):156-63. PubMed ID: 20018492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.